FAB Fusion Antibodies plc
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing and engineering, antibody humanization and rational affinity maturation platform, recombinant protein expressions, and stable cell line development and cGMP scale up services. Its products are used in the pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company has a collaboration agreement with the National Cancer Institute for the use of OptiMAL. Fusion Antibodies plc was incorporated in 2000 and is based in Belfast, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About Fusion Antibodies (LON: FAB)
›
Fusion Antibodies (LON: FAB) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 27 employees.
The shares were at 4.250 GBp on 19 November 2026, down 67.9% over 52 weeks.
Its market capitalisation is 5.32M GBP.
Fusion Antibodies reports return on equity of -70.8%, an operating margin of -52.6% and revenue up 67.8% year over year.
It holds more cash than debt, a net cash position of 712.00K GBP. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.